Brixadi (buprenorphine) is a prescription drug that’s used to treat opioid use disorder (OUD). Brixadi comes as a liquid solution in a prefilled syringe. You’ll receive Brixadi as an injection under ...

Brixadi (buprenorphine) is a prescription injection that’s used to treat opioid use disorder (OUD). It comes as a solution in prefilled syringes and is given weekly or monthly by a healthcare ...

Credit: Getty Images. Brixadi (buprenorphine) is an investigational, extended-release weekly and monthly subcutaneous injection for moderate to severe opioid use disorder. The Food and Drug ...

LUND, Sweden, June 26, 2021 /PRNewswire/ — Camurus (NASDAQ STO: CAMX) announced today that the New Drug Application (NDA) by Camurus’ US licensee Braeburn for BrixadiTM (buprenorphine) ...

BRIXADI is the first and only long-acting buprenorphine injectable with both weekly and monthly doses. Patients currently on a transmucosal buprenorphine-containing product can be switched to an ...

BRIXADI is now available for healthcare settings and pharmacies through a restricted distribution program called the BRIXADI REMS and is administered only by a healthcare professional. PLYMOUTH ...

PLYMOUTH MEETING, Pa., June 15, 2021 /PRNewswire/ — Braeburn announces that today the New Drug Application (NDA) for BRIXADI (buprenorphine) extended-release injection for subcutaneous (SC) use (CIII) ...

Keep reading for specific information about the dosage of Brixadi, including its strengths and how the medication is given. For a comprehensive look at Brixadi, see this article. Note: This article ...

Credit: Getty Images. The resubmitted NDA was in response to a Complete Response Letter issued by the FDA in December 2021. The Food and Drug Administration (FDA) has accepted the resubmitted New Drug ...

PLYMOUTH MEETING, Pa., June 26, 2021 /PRNewswire/ — Braeburn announces that the New Drug Application (NDA) for BRIXADI (buprenorphine) extended-release weekly and monthly injection for subcutaneous ...